ATE454895T1 - Verfahren zur induktion einer selektiv unterdrückten immunantwort - Google Patents

Verfahren zur induktion einer selektiv unterdrückten immunantwort

Info

Publication number
ATE454895T1
ATE454895T1 AT02750483T AT02750483T ATE454895T1 AT E454895 T1 ATE454895 T1 AT E454895T1 AT 02750483 T AT02750483 T AT 02750483T AT 02750483 T AT02750483 T AT 02750483T AT E454895 T1 ATE454895 T1 AT E454895T1
Authority
AT
Austria
Prior art keywords
cells
blood
recipient
skin
induce
Prior art date
Application number
AT02750483T
Other languages
English (en)
Inventor
Richard L Edelson
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE454895T1 publication Critical patent/ATE454895T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/369—Temperature treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT02750483T 2001-08-13 2002-08-13 Verfahren zur induktion einer selektiv unterdrückten immunantwort ATE454895T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31200401P 2001-08-13 2001-08-13
PCT/US2002/025703 WO2003015850A1 (en) 2001-08-13 2002-08-13 Method for inducing selectively suppressed immune response

Publications (1)

Publication Number Publication Date
ATE454895T1 true ATE454895T1 (de) 2010-01-15

Family

ID=23209429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02750483T ATE454895T1 (de) 2001-08-13 2002-08-13 Verfahren zur induktion einer selektiv unterdrückten immunantwort

Country Status (7)

Country Link
US (2) US7625557B2 (de)
EP (1) EP1427462B1 (de)
AT (1) ATE454895T1 (de)
CA (1) CA2457015C (de)
DE (1) DE60235097D1 (de)
ES (1) ES2339752T3 (de)
WO (1) WO2003015850A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
CA2468197A1 (en) * 2001-11-29 2003-06-05 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
AU2004237844B2 (en) * 2003-12-23 2011-01-27 Therakos, Inc. Extracorporeal photopheresis in combination with anti-TNF treatment
CN105102612B (zh) 2012-12-06 2020-11-17 恩立夫克治疗有限责任公司 治疗性凋亡细胞制剂、其制备方法以及其用途
US20160114095A1 (en) * 2014-10-27 2016-04-28 Fenwal, Inc. Methods and systems for collecting mononuclear cells
GB201513278D0 (en) * 2015-07-03 2015-09-09 Transimmune Ag And Yale University Device and method for obtaining immunostimulatory antigen-presenting cells
LT3445354T (lt) * 2016-04-20 2022-09-12 New Frontier Labs, Llc Azelaino rūgšties esteriai, naudojami gydant atsparumą insulinui
US11679193B2 (en) * 2017-12-20 2023-06-20 Fenwal, Inc. System and method of collecting and infusing an apoptotic white blood cell component and a transplant component
JP2022529947A (ja) * 2019-04-16 2022-06-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ドナーアポトーシス白血球が誘導する移植免疫寛容のバイオマーカー
KR20240040111A (ko) * 2021-07-29 2024-03-27 트랜스이뮨 아게 선택적 관용화 - 관용성 수지상 세포를 선택적으로 생성하는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US66021A (en) 1867-06-25 William edwin heath
US4321918A (en) * 1979-10-23 1982-03-30 Clark Ii William T Process for suppressing immunity to transplants
US4683889A (en) * 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5167657A (en) 1988-11-14 1992-12-01 Baxter International Inc. Plastic composition with anti-hemolytic effect
US5147289A (en) 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
DK16393D0 (da) 1993-02-12 1993-02-12 Silcon Power Electronics As Noedstroemsanlaeg
AU2331597A (en) 1996-03-22 1997-10-10 Yale University Methods for inducing immune responsiveness in a subject
US6194204B1 (en) * 1996-08-02 2001-02-27 Center For Blood Research, Inc. Enrichment of dendritic cells from blood
EP1056834A2 (de) * 1998-02-20 2000-12-06 The Rockefeller University Antigenpräsentation auf dendritische zellen mittels apoptotischer zellen
EP1068300A1 (de) * 1998-03-30 2001-01-17 I.D.M. Immuno-Designed Molecules Suppressive von monozyten ableitbare zellen, deren herstellungsverfahren und deren verwendung in pharmazeutischen erzeugnissen
US20050084966A1 (en) * 1999-04-20 2005-04-21 Edelson Richard L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CA2368855C (en) 1999-04-20 2012-05-29 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US6800300B1 (en) * 2000-03-31 2004-10-05 Vasogen Ireland Limited Method for treating autoimmune and alloimmune diseases
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells

Also Published As

Publication number Publication date
EP1427462B1 (de) 2010-01-13
DE60235097D1 (de) 2010-03-04
EP1427462A4 (de) 2006-06-07
WO2003015850A1 (en) 2003-02-27
US20030059426A1 (en) 2003-03-27
CA2457015A1 (en) 2003-02-27
CA2457015C (en) 2012-03-13
US7988951B2 (en) 2011-08-02
US20100183735A1 (en) 2010-07-22
EP1427462A1 (de) 2004-06-16
ES2339752T3 (es) 2010-05-25
US7625557B2 (en) 2009-12-01

Similar Documents

Publication Publication Date Title
von Stebut et al. Cutaneous leishmaniasis: Distinct functions of dendritic cells and macrophages in the interaction of the host immune system with Leishmania major
Bogdan Natural killer cells in experimental and human leishmaniasis
Plock et al. The influence of timing and frequency of adipose-derived mesenchymal stem cell therapy on immunomodulation outcomes after vascularized composite allotransplantation
ATE454895T1 (de) Verfahren zur induktion einer selektiv unterdrückten immunantwort
Goedhart et al. CXCR4, but not CXCR3, drives CD8+ T‐cell entry into and migration through the murine bone marrow
EP1810691A3 (de) Immuntherapie zur Umkehrung einer Immunsuppression
de Veer et al. Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly (I: C) containing liposomes, in aqueous or oil-based formulations
Xia et al. High‐mobility group box 1 accelerates early acute allograft rejection via enhancing IL‐17+ γδ T‐cell response
Pinheiro et al. The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
Vallejo et al. Cellular pathway (s) of antigen processing in fish APC: effect of varying in vitro temperatures on antigen catabolism
Thomson et al. Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance
Schirrmacher et al. T cell memory, anergy and immunotherapy in breast cancer
JP2014516538A5 (de)
Kautz‐Neu et al. Leishmaniasis, contact hypersensitivity and graft‐versus‐host disease: understanding the role of dendritic cell subsets in balancing skin immunity and tolerance
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
Froese et al. Brief communication: Neuraminidase-induced enhancement of tumor growth in mice
ATE442434T1 (de) Verfahren zur unterdrückung einer immunsystemreaktion gegen gewebe- oder zelltransplantate
US20210369774A1 (en) Micro-rna-155 enhances the efficacy of dendritic cell vaccine for cancer
Kapessidou et al. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells
Gansauge et al. Effectivity of long antigen exposition dendritic cell therapy (LANEXDC®) in the palliative treatment of pancreatic cancer
WO2018015815A3 (en) Plasmodium with histamine releasing factor (hrf) deficiency for use as a vaccine
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
MX2022004186A (es) Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.
Hepiretihan et al. Immune responses on allograft heart transplantation in inbred rats infected withEchinococcosis multilocularis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties